重组人血管内皮抑制素对晚期胃癌患者血清肿瘤标志物水平的影响

Effect of recombinant human endostatin on serum tumor markers levels in patients with advanced gastric cancer

目的探讨重组人血管内皮抑制素对晚期胃癌患者血清糖链抗原199(CA199)、癌抗原724(CA724)、血管内皮生长因子(VEGF)、S100A4蛋白(S100A4)水平的影响。方法纳入2021年6月2023年3月新乡市中心医院收治的86例晚期胃癌患者,根据治疗方法不同均分A组(替吉奥+顺铂方案化疗)和B组(于A组基础上予以重组人血管内皮抑制素)2组,每组43例,比较2组血清肿瘤标志物水平变化。结果B组临床获益率高于A组(χ^(2)=4.074,P=0.044)。治疗后,B组患者血清CA199、CA724、VEGF、S100A4水平均低于A组(t=33.274,P<0.001;t=10.686,P<0.001;t=15.620,P<0.001;t=7.536,P<0.001),而KPS评分高于A组(t=5.938,P<0.001)。2组患者不良反应总发生率比较差异无统计学意义(χ^(2)=0.551,P=0.458)。结论晚期胃癌患者应用重组人血管内皮抑制素安全有效,能够降低机体内血清肿瘤标志物水平,改善患者健康状况。

Objective To investigate the effect of recombinant human endostatin on serum levels of glycoprotein antigen 199(CA199),cancer antigen 724(CA724),vascular endothelial growth factor(VEGF)and S100A4 protein(S100A4)in patients with advanced gastric cancer.Methods Eighty-six patients with advanced gastric cancer admitted to Xinxiang Central Hospital from June 2021 to March 2023 were divided into two groups according to different treatment methods,with 43 patients in each group,which were divided into the group A(chemotherapy with S-1+cisplatin regimen)and the group B(recombinant human endostatin was given on the basis of the group A),the serum tumor markers levels were compared between the two groups.Results The clinical benefit rate of the group B was higher than that of the group A(χ^(2)=4.074,P=0.044).After treatment,the serum levels of CA199,CA724,VEGF and S100A4 in the group B were lower than those in the group A(t=33.274,P<0.001;t=10.686,P<0.001;t=15.620,P<0.001;t=7.536,P<0.001),while the KPS score was higher than that in the group A(t=5.938,P<0.001).There was no statistically significant difference in the total incidence of adverse reactions between the two groups of patients(χ^(2)=0.551,P=0.458).Conclusion The application of recombinant human endostatin in patients with advanced gastric cancer can reduce the level of serum tumor markers in the body and improve the health status of patients,with remarkable curative effect and no increase in the incidence of adverse reactions.